Unity Biotechnology Stock Current Ratio
| UBX Stock | USD 1.21 0.02 1.68% |
Unity Biotechnology fundamentals help investors to digest information that contributes to Unity Biotechnology's financial success or failures. It also enables traders to predict the movement of Unity Stock. The fundamental analysis module provides a way to measure Unity Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unity Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 5.94 | 10.69 |
Unity | Current Ratio |
Unity Biotechnology Company Current Ratio Analysis
Unity Biotechnology's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Unity Biotechnology Current Ratio | 4.13 X |
Most of Unity Biotechnology's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Unity Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Unity Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Unity Biotechnology is extremely important. It helps to project a fair market value of Unity Stock properly, considering its historical fundamentals such as Current Ratio. Since Unity Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Unity Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Unity Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Unity Current Ratio Historical Pattern
Today, most investors in Unity Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Unity Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Unity Biotechnology current ratio as a starting point in their analysis.
Unity Biotechnology Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Unity Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Unity Biotechnology has a Current Ratio of 4.13 times. This is 41.92% higher than that of the Biotechnology sector and 41.0% lower than that of the Health Care industry. The current ratio for all United States stocks is 91.2% lower than that of the firm.
Unity Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Unity Biotechnology's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Unity Biotechnology could also be used in its relative valuation, which is a method of valuing Unity Biotechnology by comparing valuation metrics of similar companies.Unity Biotechnology is currently under evaluation in current ratio category among its peers.
Unity Fundamentals
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 11.71 M | ||||
| Shares Outstanding | 16.85 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 20.54 % | ||||
| Number Of Shares Shorted | 303.04 K | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 6.54 X | ||||
| Gross Profit | (35.22 M) | ||||
| EBITDA | (37.28 M) | ||||
| Net Income | (39.86 M) | ||||
| Cash And Equivalents | 64.51 M | ||||
| Cash Per Share | 9.26 X | ||||
| Total Debt | 26.99 M | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 4.13 X | ||||
| Book Value Per Share | 0.84 X | ||||
| Cash Flow From Operations | (37.09 M) | ||||
| Short Ratio | 7.70 X | ||||
| Earnings Per Share | (1.28) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 20.05 M | ||||
| Total Asset | 65.69 M | ||||
| Retained Earnings | (484.35 M) | ||||
| Working Capital | 38.77 M | ||||
| Net Asset | 65.69 M |
About Unity Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Unity Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unity Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unity Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.